Amgen Inc. income statement & cash flow
In the fiscal year ended Dec 31, 2025, Amgen Inc. reported net income of $7.71B on revenue of $36.75B. Operating cash flow was $9.96B and capital expenditures were $1.86B, leaving $8.10B of free cash flow (operating cash flow minus capital expenditures).
Income statement and cash flow summary
| Fiscal year ended | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $22.99B | $22.85B | $23.75B | $23.36B | $25.42B | $25.98B | $26.32B | $28.19B | $33.42B | $36.75B |
| Operating income | $9.79B | $9.97B | $10.26B | $9.67B | $9.14B | $7.64B | $9.57B | $7.90B | $7.26B | $9.08B |
| Net income | $7.72B | $1.98B | $8.39B | $7.84B | $7.26B | $5.89B | $6.55B | $6.72B | $4.09B | $7.71B |
| Diluted EPS | $10.24 | $2.69 | $12.62 | $12.88 | $12.31 | $10.28 | $12.11 | $12.49 | $7.56 | $14.23 |
| Operating cash flow | $10.35B | $11.18B | $11.30B | $9.15B | $10.50B | $9.26B | $9.72B | $8.47B | $11.49B | $9.96B |
| Capital expenditures | $738.00M | $664.00M | $738.00M | $618.00M | $608.00M | $880.00M | $936.00M | $1.11B | $1.10B | $1.86B |
| Reported in | 10-K 2019 | 10-K 2020 | 10-K 2021 | 10-K 2022 | 10-K 2023 | 10-K 2024 | 10-K 2025 | 10-K 2026 | 10-K 2026 | 10-K 2026 |
Margins
Each figure divided by revenue for the same fiscal year.
| Fiscal year ended | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| Dec 2025 | — | 24.7% | 21.0% |
| Dec 2024 | — | 21.7% | 12.2% |
| Dec 2023 | — | 28.0% | 23.8% |
| Dec 2022 | — | 36.3% | 24.9% |
| Dec 2021 | — | 29.4% | 22.7% |
Source: SEC EDGAR XBRL company facts for CIK 318154 (raw data). Most recent filing in this dataset: 10-Q filed Aug 5, 2026. SEC data file dated Nov 3, 2026; page built Nov 5, 2026. Figures are as most recently reported, including restatements. How we select figures.